الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 202 |  |  |
| | | from | 202 | | |
Abstract
ARDS is a serious lung disease that may end up with lethal hyper-inflammation and cytokine storm or progress to irreversible pulmonary fibrosis. RSV is a natural polyphenol with remarkable anti-inflammatory benefits, but poor bioavailability limits its clinical applications as large doses are required to attain a satisfactory effect. As a result, efforts are made to provide an ideal drug delivery system to overcome RSV’s physicochemical and pharmacokinetic limitations and optimize its systemic efficiency.
In the current study, lipid core nanocapsules were selected for the oral delivery of RSV and was evaluated for its role in prevention and treatment of acute and chronic lung injury, respectively. Ninety-six adult male albino rats (200-220 g) were used for the experiment where pulmonary injury was induced by a single intratracheal instillation of BLM at a dose of 5 mg/Kg. The animals were randomized into 5 groups: group I (Control group): 32 rats subdivided equally into 4 subgroups (A, B, C, D), each received intratracheal PBS and treated orally with a single dose of 0.9% saline, LNCs, RSV, RSV-LNCs respectively at a dose of 10 mg/kg by oral gavage. Half of the animals were euthanized on day 3, and the other half at day 21. group II (BLM group): 16 rats subdivided randomly into 2 equal subgroups. Subgroup IIA: each rat received BLM and euthanized at day 3. Subgroup IIB: each rat received BLM and euthanized at day 21. group ΙΙΙ (LNCs + BLM): 16 rats subdivided randomly into 2 equal subgroups. Subgroup ΙΙΙA: each rat received a single dose of LNCs at a dose of 10 mg/kg by oral gavage followed 4 hours later by BLM and euthanized at day 3. Subgroup ΙΙΙB: each rat received BLM and on days 10-21, each rat received a daily dose of 10 mg/kg of LNCs by oral gavage and euthanized at day 21.